Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor

A technology of kinase inhibitors and compositions, which is applied in the direction of drug combinations, medical preparations containing active ingredients, active ingredients of boron compounds, etc., and can solve problems such as narrow therapeutic index

Inactive Publication Date: 2007-09-26
比拉勒·皮佩蒂
View PDF50 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Instead, most have very narrow therapeutic indices

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
  • Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
  • Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The term "carcinoma" in an animal refers to the presence of cells with typical properties of carcinogenic cells, such as uncontrolled proliferation, immortalization, metastatic potential, rapid growth and proliferation rates, and certain morphological properties. Typically, cancer cells take the form of tumors, but such cells can exist alone in animals, or circulate in the bloodstream as separate cells, such as leukemia cells.

[0017] As used herein, unless otherwise indicated, "abnormal cell growth" refers to cell growth independent of normal regulatory mechanisms (eg, loss of contact inhibition). It includes the abnormal growth of (1) neoplastic cells (tumors) that proliferate by expressing mutated tyrosine kinases or overexpressing tyrosine kinase receptors; (2) benign and malignant cells of other proliferative disorders , where aberrant tyrosine kinase activation occurs; (4) any tumor that proliferates through receptor tyrosine kinases; (5) any tumor that prolifera...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for method for manufacturing a medicament intended for treating tumors or tumor metastases in a patient, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and bortezomib is used, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and bortezomib combination in a combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCI (also known as Tarceva TM).

Description

Background of the invention [0001] The present invention relates to compositions and methods for treating cancer patients. In particular, the invention relates to a process for the preparation of a medicament comprising bortezomib and an epidermal growth factor receptor (EGFR) kinase inhibitor. [0002] Cancer is the general name for a wide variety of cellular malignancies characterized by uncontrolled growth, lack of differentiation, and the ability to invade local tissues and metastasize. These malignancies affect every tissue and organ in the body at varying rates. [0003] A variety of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer. The most commonly used classes of anticancer agents include: DNA alkylating agents (eg, cyclophosphamide, ifosfamide), antimetabolites (eg, methotrexate, folate antagonists, and 5-fluorouracil, pyrimidine antagonists), microbes Tube disrupting agents (eg, vincristine, vinblastine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/69A61K31/517A61P35/00
CPCA61K45/06A61K31/69A61K31/517A61K31/4184A61P35/00A61P35/02A61P35/04A61P43/00A61K2300/00
Inventor 比拉勒·皮佩蒂
Owner 比拉勒·皮佩蒂
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com